INTELLINETICS, INC.

Intellinetics, Inc. Email List: Click to Subscribe

View Company Website: Click to View

Market Data: Yahoo Finance, Bloomberg, SEC Filings

Report Link: Updated Research Report (Dated November 18, 2024)

Symbol: INLX
Analyst: Howard Halpern
Taglich Rating: Speculative Buy
Price Target: $19.00
Time Horizon: 12 Months
Rating Established: February 26, 2018
Price When Established: $7.15
Most Recent Report: November 18, 2024
Price When Issued: $13.00

What’s New

Intellinetics Announces IPAS Partnership

On January 23, 2025, Intellinetics Inc. announced IPAS will be entering into the K-12 market through an expansion of its partnership with Skyward, a school administration software provider. This expanded partnership with Skyward builds on their existing collaboration the company’s YellowFolder operations. Skyward has worked with more than 2,500 school districts. The company anticipates this expanded partnership is a significant step forward in the K-12 sector as a key market for generating significant IPAS SaaS revenue.

Intellinetics IPAS for K-12 utilizes artificial intelligence (AI) to virtually eliminate all paper and manual steps in the scanning, capture, indexing, and filing of a school district’s accounts payable (AP) Invoices and automates the approval process while improving transparency and audit capabilities. This means once approved, invoices are systematically and securely stored in the electronic document management system for fingertip auditing and archiving.

Company Description

Intellinetics Inc., headquartered in Columbus, OH, has developed IntelliCloud™ a software solutions platform enabling customers to capture and manage documents across its operations. IntelliCloud is a secure document management solution for organizations that have critical document requirements such as for audit trails and credentialing. The company’s primary targets are organization and governmental agencies within the health and human services and education (K – 12) markets.

Disclaimer
Please view our current disclosure and disclaimer on our most recent research report.